New COVID-19 vaccine shows promise in small trial
NCT ID NCT05279456
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a new COVID-19 vaccine called SpikoGen in 39 adults who had never received a COVID-19 vaccine. Participants received two doses one month apart, followed by a third booster dose either one or three months later. The goal was to see how well the vaccine triggered an immune response and whether it was safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SpikoGen vaccine (recombinant spike protein with Advax-CpG55.2 adjuvant)
- What this could lead to
- If successful, this could provide a safe and effective COVID-19 vaccine option for people who have not yet been vaccinated.
- What could go wrong
- This is a small, early-phase trial with only 39 participants, so results may not apply to the general population. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ARASMI
Adelaide, South Australia, 5042, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?